Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AKRO

AKRO - Akero Therapeutics Inc Stock Price, Fair Value and News

$54.65 
Market Closed

16/100

AKRO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

16/100

AKRO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$43.64

Target 3M

$49.09

Target 6M

$46.37

AKRO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKRO Price Action

Last 7 days

0.4%

Last 30 days

0.9%

Last 90 days

22.0%

Trailing 12 Months

83.7%

AKRO RSI Chart

AKRO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKRO Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

-15.36

Price/Sales (Trailing)

106.92

Price/Free Cashflow

-17.98

AKRO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$43.64

Target 3M

$49.09

Target 6M

$46.37

AKRO Fundamentals

AKRO Revenue

Revenue (TTM)

42.1M

Rev. Growth (Yr)

10.49%

Rev. Growth (Qtr)

0.07%

AKRO Earnings

Earnings (TTM)

-292.8M

Earnings Growth (Yr)

-12.19%

Earnings Growth (Qtr)

-15.69%

AKRO Profitability

Return on Equity

-30.58%

Return on Assets

-29.12%

Free Cashflow Yield

-5.56%

AKRO Investor Care

Shares Dilution (1Y)

17.93%

Diluted EPS (TTM)

-3.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202541.7M042.1M0
202428.4M34.0M36.4M38.0M
20238.9M14.0M19.1M24.2M
20220003.9M
20210000
Get all data in R, Python etc through our Historical Stock Data APIs

About Akero Therapeutics Inc

AKRO
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEakerotx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES44

Akero Therapeutics Inc Frequently Asked Questions

AKRO is the stock ticker symbol of Akero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Dec 09 2025, market cap of Akero Therapeutics Inc is 4.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AKRO's fair value in chart for subscribers.

The fair value guage provides a quick view whether AKRO is over valued or under valued. Whether Akero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKRO.

As of Tue Dec 09 2025, AKRO's PE ratio (Price to Earnings) is -15.36 and Price to Sales (PS) ratio is 106.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKRO PE ratio will change depending on the future growth rate expectations of investors.